Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer

NCT00500110 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Imatinib Mesylate
DRUG: Leuprolide
DRUG: Goserelin Acetate

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]